Published in Mol Biosyst on November 01, 2013
A Quantitative Proteomics Approach to Clinical Research with Non-Traditional Samples. Proteomes (2016) 0.84
Tumor Necrosis Factor-α, Matrix-Metalloproteinases 8 and 9 Levels in the Saliva Are Associated with Increased Hemoglobin A1c in Type 1 Diabetes Subjects. PLoS One (2015) 0.79
Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. Proteomics (2016) 0.78
α-2-macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus. Dis Markers (2015) 0.76
A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med (2015) 0.76
Comparative salivary proteome of hepatitis B- and C-infected patients. PLoS One (2014) 0.75
Saliva diagnostics - Current views and directions. Exp Biol Med (Maywood) (2016) 0.75
An unbiased protein association study on the public human proteome reveals biological connections between co-occurring protein pairs. J Proteome Res (2017) 0.75
A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Glycoconj J (2017) 0.75
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35
Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care (2000) 4.63
Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care (2001) 4.05
HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med (2007) 3.69
Tests of glycemia in diabetes. Diabetes Care (2004) 3.35
Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes (2011) 3.16
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care (2007) 2.49
High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications (2002) 2.42
Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem (1988) 2.41
Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control: a randomized controlled trial. Diabetes Care (2005) 2.41
Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol (2000) 2.11
Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care (2009) 2.08
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol (2002) 2.08
Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol (2007) 1.98
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol (2007) 1.96
Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes (2002) 1.81
Performance of A1C for the classification and prediction of diabetes. Diabetes Care (2010) 1.80
Review of hemoglobin A(1c) in the management of diabetes. J Diabetes (2009) 1.79
Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res (2008) 1.76
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res (2005) 1.71
Blood glycoprotein levels in diabetes mellitus. Diabetologia (1976) 1.58
Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes (2005) 1.53
Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol (1983) 1.52
Reliability of blood glucose monitoring by patients with diabetes mellitus. Am J Med (1984) 1.48
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care (2003) 1.43
Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res (2009) 1.43
Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res (2006) 1.40
Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes (2005) 1.40
Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota /lambda and plays a role in microtubule dynamics in the early secretory pathway. J Biol Chem (2001) 1.39
A comparison of ghrelin, glucose, alpha-amylase and protein levels in saliva from diabetics. J Biochem Mol Biol (2007) 1.35
Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation (2004) 1.34
Tanis: a link between type 2 diabetes and inflammation? Diabetes (2002) 1.30
Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med (2000) 1.23
Structure of human salivary alpha-amylase at 1.6 A resolution: implications for its role in the oral cavity. Acta Crystallogr D Biol Crystallogr (1996) 1.20
Proteome analysis of skeletal muscle from obese and morbidly obese women. Diabetes (2005) 1.18
Identification of a new potential airway irritation marker, palate lung nasal epithelial clone protein, in human nasal lavage fluid with two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time of flight. Electrophoresis (2001) 1.12
Increased levels of acute-phase serum proteins in diabetes. Metabolism (1989) 1.09
Glycosylation of serum albumin: elevated glycosyl-albumin in diabetic patients. FEBS Lett (1979) 1.08
Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2009) 1.06
Albumin as a zinc carrier: properties of its high-affinity zinc-binding site. Biochem Soc Trans (2008) 1.02
Stem cell approaches for diabetes: towards beta cell replacement. Genome Med (2011) 1.02
Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) (1967) 1.00
Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Diabetes Metab Res Rev (2006) 0.99
Immunoglobulins and innate antimicrobial factors in whole saliva of patients with insulin-dependent diabetes mellitus. J Dent Res (1986) 0.95
The ORF3 protein of hepatitis E virus interacts with hemopexin by means of its 26 amino acid N-terminal hydrophobic domain II. Biochemistry (2008) 0.95
Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. OMICS (2011) 0.95
Localized-statistical quantification of human serum proteome associated with type 2 diabetes. PLoS One (2008) 0.93
Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation. Biophys Chem (2003) 0.93
Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci (Lond) (2008) 0.93
Exploring salivary proteomes in edentulous patients with type 2 diabetes. Mol Biosyst (2012) 0.92
Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. J Atheroscler Thromb (2006) 0.92
alpha1-Macroglobulin and reduced basement-membrane degradation in diabetes. Lancet (1976) 0.91
Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia (2012) 0.91
Cystatin S: a cysteine proteinase inhibitor of human saliva. J Biochem (1984) 0.90
Reproducibility of the new diagnostic criteria for impaired glucose tolerance. Am J Epidemiol (1985) 0.90
Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells. J Clin Invest (1998) 0.88
Effect of nonenzymatic glycation on functional and structural properties of hemoglobin. Biophys Chem (2005) 0.87
Nonenzymatic glycosylation of serum IgG and its effect on antibody activity in patients with diabetes mellitus. Diabetes (1987) 0.86
Characterization of a new cysteine proteinase inhibitor of human saliva, cystatin SN, which is immunologically related to cystatin S. FEBS Lett (1986) 0.86
Alterations of the salivary secretory peptidome profile in children affected by type 1 diabetes. Mol Cell Proteomics (2010) 0.86
Serum alpha 2-macroglobulin levels in diabetes. J Clin Pathol (1980) 0.86
Urinary proteins and red blood cell membrane negative charges in diabetes mellitus. Clin Chim Acta (1990) 0.85
Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci (2009) 0.85
Association of the uteroglobin gene polymorphism with IgA nephropathy. Am J Kidney Dis (2002) 0.83
Abnormal serum immunoglobulin concentrations in patients with diabetes mellitus. Clin Chim Acta (1991) 0.82
Complement C3 deficiency prevent against the onset of streptozotocin-induced autoimmune diabetes involving expansion of regulatory T cells. Clin Immunol (2011) 0.82
Serum immunoglobulin concentrations in diabetic patients. Diabet Med (1994) 0.81
Recurrence of autoimmunity in pancreas transplant patients: research update. Diabetes Manag (Lond) (2011) 0.81
Comparative hepatic proteome analysis between lean and obese rats fed a high-fat diet reveals the existence of gender differences. Proteomics (2012) 0.80
Moderate glycation of serum albumin affects folding, stability, and ligand binding. Clin Chim Acta (2011) 0.80
Hemopexin is up-regulated in plasma from type 1 diabetes mellitus patients: Role of glucose-induced ROS. J Proteomics (2012) 0.80
The effects of home monitoring by public health nurse on individuals' diabetes control. Appl Nurs Res (2006) 0.77
The association of non-insulin-dependent diabetes mellitus and hypertension with urinary excretion of albumin and transferrin. Am J Kidney Dis (1993) 0.76
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect (2012) 4.89
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Optimal tests for rare variant effects in sequencing association studies. Biostatistics (2012) 4.69
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Third molars associated with periodontal pathology in older Americans. J Oral Maxillofac Surg (2005) 2.40
Periodontal disease and coronary heart disease: a reappraisal of the exposure. Circulation (2005) 2.36
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol (2009) 2.20
Systemic effects of periodontitis: epidemiology of periodontal disease and cardiovascular disease. J Periodontol (2005) 2.19
Fetal exposure to oral pathogens and subsequent risk for neonatal intensive care admission. J Periodontol (2009) 2.17
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol (2003) 2.12
Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med (2003) 2.06
Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. J Am Dent Assoc (2002) 1.95
Associations between IgG antibody to oral organisms and carotid intima-medial thickness in community-dwelling adults. Atherosclerosis (2005) 1.94
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet (2006) 1.74
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
The Periodontitis and Vascular Events (PAVE) pilot study: adverse events. J Periodontol (2008) 1.55
The relationship between self-reported history of endodontic therapy and coronary heart disease in the Atherosclerosis Risk in Communities Study. J Am Dent Assoc (2009) 1.54
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol (2009) 1.52
Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. Am Heart J (2012) 1.52
Periodontal disease early in pregnancy is associated with maternal systemic inflammation among African American women. J Periodontol (2008) 1.50
Oral reconstructive and corrective considerations in periodontal therapy. J Periodontol (2005) 1.49
Pharmacologic prophylaxis and risk factors for intraoperative floppy-iris syndrome in phacoemulsification performed by resident physicians. J Cataract Refract Surg (2010) 1.47
Exploring the relationship between periodontal disease and pregnancy complications. J Am Dent Assoc (2006) 1.47
Periodontal regeneration. J Periodontol (2005) 1.47
Relationships among clinical measures of periodontal disease and their associations with systemic markers. Ann Periodontol (2002) 1.46
The oral conditions and pregnancy study: periodontal status of a cohort of pregnant women. J Periodontol (2004) 1.46
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J Mol Biol (2006) 1.42
Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. Periodontol 2000 (2003) 1.42
Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41
Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol (2005) 1.40
Maternal periodontal disease in early pregnancy and risk for a small-for-gestational-age infant. Am J Obstet Gynecol (2006) 1.31
Electronic communications and home blood pressure monitoring (e-BP) study: design, delivery, and evaluation framework. Contemp Clin Trials (2007) 1.31
Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. Periodontol 2000 (2006) 1.29
Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. Genet Epidemiol (2011) 1.29
Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol (2005) 1.26
The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart J (2006) 1.26
Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol (2002) 1.25
Exploring the genetic basis of chronic periodontitis: a genome-wide association study. Hum Mol Genet (2013) 1.23
Arsenic and the epigenome: interindividual differences in arsenic metabolism related to distinct patterns of DNA methylation. J Biochem Mol Toxicol (2013) 1.19
Periodontal pathology associated with asymptomatic third molars. J Oral Maxillofac Surg (2002) 1.18
Periodontitis and diabetes associations with measures of atherosclerosis and CHD. Atherosclerosis (2012) 1.18
Maternal periodontal disease, systemic inflammation, and risk for preeclampsia. Am J Obstet Gynecol (2008) 1.17
A perspective on the potential cardioprotective benefits of periodontal therapy. Am Heart J (2005) 1.16
Porphyromonas gingivalis infection in pregnant mice is associated with placental dissemination, an increase in the placental Th1/Th2 cytokine ratio, and fetal growth restriction. Infect Immun (2003) 1.15
Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome. Genet Epidemiol (2010) 1.14
Postdischarge pharmacist medication reconciliation: impact on readmission rates and financial savings. J Am Pharm Assoc (2003) (2013) 1.13
A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis (2010) 1.12
Clinical risk factors associated with incidence and progression of periodontal conditions in pregnant women. J Clin Periodontol (2005) 1.11
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Neonatal genome-wide methylation patterns in relation to birth weight in the Norwegian Mother and Child Cohort. Am J Epidemiol (2014) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Progression of periodontal disease in the second/third molar region in subjects with asymptomatic third molars. J Oral Maxillofac Surg (2006) 1.10
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Vitamin D status and periodontal disease among pregnant women. J Periodontol (2010) 1.08
Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis (2012) 1.07
Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine (Phila Pa 1976) (2011) 1.07
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
Persistently high levels of periodontal pathogens associated with preterm pregnancy outcome. J Periodontol (2007) 1.07
Antibodies to periodontal organisms are associated with decreased kidney function. The Dental Atherosclerosis Risk In Communities study. Blood Purif (2006) 1.06
Third molars associated with periodontal pathology in the Third National Health and Nutrition Examination Survey. J Oral Maxillofac Surg (2004) 1.06
Relationship of periodontal disease and tooth loss to prevalence of coronary heart disease. J Periodontol (2004) 1.06
IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein. Hum Genet (2008) 1.06
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Maternal serum C-reactive protein concentration early in pregnancy and subsequent pregnancy loss. Am J Perinatol (2005) 1.03
Porphyromonas gingivalis infection during pregnancy increases maternal tumor necrosis factor alpha, suppresses maternal interleukin-10, and enhances fetal growth restriction and resorption in mice. Infect Immun (2003) 1.03